Last: | $724.87 |
---|---|
Change Percent: | 0.98% |
Open: | $725 |
Close: | $724.87 |
High: | $727.9915 |
Low: | $718.3 |
Volume: | 2,597,582 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$724.87 | $725 | $724.87 | $727.9915 | $718.3 | 2,597,582 | 04-25-2024 |
$732.2 | $752.64 | $732.2 | $752.64 | $728.785 | 2,052,625 | 04-24-2024 |
$745.69 | $741.2 | $745.69 | $746.16 | $731.44 | 2,042,029 | 04-23-2024 |
$731.33 | $729.74 | $731.33 | $737.88 | $725.42 | 2,354,096 | 04-22-2024 |
$726.31 | $749.16 | $726.31 | $750.01 | $722.07 | 3,505,526 | 04-19-2024 |
$745.95 | $749.42 | $745.95 | $752.1988 | $743.77 | 1,717,347 | 04-18-2024 |
$750.77 | $759.2 | $750.77 | $771.83 | $744.8776 | 3,069,367 | 04-17-2024 |
$746.74 | $751.68 | $746.74 | $753.14 | $743 | 2,569,799 | 04-16-2024 |
$750.77 | $760.07 | $750.77 | $768 | $749.52 | 2,358,569 | 04-15-2024 |
$751.64 | $759.57 | $751.64 | $763.5 | $749.785 | 2,495,037 | 04-12-2024 |
$759.59 | $759.78 | $759.59 | $763.33 | $750.67 | 1,594,834 | 04-11-2024 |
$761.98 | $751.28 | $761.98 | $765.26 | $746.83 | 1,700,296 | 04-10-2024 |
$757.24 | $777.64 | $757.24 | $777.82 | $750.65 | 2,464,837 | 04-09-2024 |
$777.29 | $785.02 | $777.29 | $785.195 | $773.35 | 1,664,153 | 04-08-2024 |
$784.21 | $765.47 | $784.21 | $786.705 | $763.09 | 2,113,429 | 04-05-2024 |
$768.08 | $781.54 | $768.08 | $787.8969 | $767.82 | 2,353,992 | 04-04-2024 |
$775.99 | $765.69 | $775.99 | $787.2475 | $765.41 | 3,044,910 | 04-03-2024 |
$763.96 | $755.07 | $763.96 | $765.07 | $753.5 | 2,596,789 | 04-02-2024 |
$760.55 | $776 | $760.55 | $777.5 | $753.82 | 2,921,338 | 04-01-2024 |
$777.96 | $780.32 | $777.96 | $793.67 | $776.44 | 3,209,424 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Eli Lilly and Company Company Name:
LLY Stock Symbol:
NYSE Market:
The Senate Committee on Health, Education, Labor, and Pensions is reportedly scrutinizing Novo Nordisk A/S (NYSE:NVO) ‘s pric...
2024-04-24 06:40:00 ET Eli Lilly 's (NYSE: LLY) Zepbound has shown it has what it takes to become a blockbuster. The weight-loss drug, following regulatory approval late last year, brought in $175 million in revenue in just its first few weeks on the market. Doctors and their patien...
On Monday, Eli Lilly and Company (NYSE:LLY) agreed to acquire a manufacturing facility from Nexus Pharmaceuticals. Th...